Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors
Brought to you by:
Series Courses

Upon completion of this activity, participants should be better able to:

  • Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies
  • List the emerging combination regimens, including BTK inhibitors
  • Discuss recent and new data supporting the role of BTK inhibitors in r/r CLL
  • Integrate patient perspectives and priorities into comprehensive care-team management of CLL